14 research outputs found

    ์˜ˆํ˜ผํ•ฉ ์Šค์›” ์•ˆ์ •ํ™” ์—ฐ์†Œ๊ธฐ์—์„œ ์žฌ์ˆœํ™˜ ์˜์—ญ์˜ ํ˜•์„ฑ์ด ์—ฐ์†Œ๋ถˆ์•ˆ์ •์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ๊ธฐ๊ณ„ํ•ญ๊ณต๊ณตํ•™๋ถ€, 2011.2. ์œค์˜๋นˆ.Maste

    ๋ฐ”์‹ค๋Ÿฌ์Šค ๋งํ† ์ œ๋‹‰ ์•„๋ฐ€๋ผ์ œ ํšจ์†Œ ์œ ์ „์ž๋ฅผ ์ด์‹ํ•œ ํ˜•์งˆ ์ „ํ™˜ ๊ฐ์ž์˜ ์œก์„ฑ ๋ฐ ํŠน์„ฑ ๋ถ„์„

    No full text
    Thesis (doctoral)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :ํ˜‘๋™๊ณผ์ • ๋†์—…์ƒ๋ฌผ๊ณตํ•™์ „๊ณต,1999.Docto

    Screening platform for assessing cellular and behavioral defects in Drosophila Melanogaster

    No full text
    For screening drugs or molecules that can modify disease pathophysiology of human disease or conduct drug screening, the use of appropriate in vivo model with low expenditure suitable for large-scale screening is essential. Drosophila Melanogaster, whose genome contain orthologs for 75% of human disease-related genes, offers a quantitative screening platform for assessing both cellular and behavioral defects that are thought to be representative of human diseases like Parkinsonโ€™s disease(PD), Huntingtonโ€™s disease(HD) or amyotrophic lateral sclerosis(ALS). Here, we present the low cost screening analysis platform available for measuring cellular and behavioral defects in Drosophila. This platform can be adapted for the use of therapeutic target discovery process as an economic and powerful in vivo screening tool for the researchers
    corecore